Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Janssen Pharmaceuticals Introduces Novel TALVEY® for the Tretament of Relapsed And Refractory Multiple Myeloma

Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, has introduced a new treatment TALVEY® (talquetamab) for patients with relapsed and refractory multiple myeloma.

TALVEY® is a remarkable bispecific T-cell engaging antibody designed to target two crucial components: CD3 on T-cells and G protein-coupled receptor class C group 5 member D (GPRC5D) on the surface of multiple myeloma cells, as well as hard keratinised tissues. Importantly, GPRC5D exhibits minimal to no expression on B-cells and their precursors.

TALVEY® (talquetamab), is developed to address the specific needs of adult patients dealing with relapsed and refractory multiple myeloma (RRMM). These are individuals who have undergone at least three prior treatment regimens, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and have experienced disease progression during their most recent treatment.

As multiple myeloma advances and patients cycle through various therapies, the challenges of managing the disease become increasingly complex, and remission periods tend to shorten. 

The introduction of talquetamab, which targets GPRC5D, has shown promising results in achieving deep responses. Unlike many other targets for multiple myeloma, GPRC5D's expression is predominantly limited to non-immune cells. This unique characteristic represents a significant breakthrough for the treatment of this heterogeneous disease.

Multiple myeloma is an incurable blood cancer that primarily affects a type of white blood cell called plasma cells, which are normally found in the bone marrow. In multiple myeloma, these malignant plasma cells undergo uncontrolled growth and transformation.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024